Australia markets close in 5 hours 39 minutes

  • ALL ORDS

    7,292.10
    -35.90 (-0.49%)
     

  • ASX 200

    7,031.10
    -34.50 (-0.49%)
     

  • AUD/USD

    0.7771
    +0.0013 (+0.17%)
     

  • OIL

    63.50
    +0.12 (+0.19%)
     

  • GOLD

    1,772.20
    +1.60 (+0.09%)
     

  • BTC-AUD

    70,628.66
    -2,346.61 (-3.22%)
     

  • CMC Crypto 200

    1,230.15
    -68.80 (-5.30%)
     

  • AUD/EUR

    0.6450
    +0.0008 (+0.12%)
     

  • AUD/NZD

    1.0805
    +0.0006 (+0.06%)
     

  • NZX 50

    12,672.19
    -95.64 (-0.75%)
     

  • NASDAQ

    13,907.67
    -134.24 (-0.96%)
     

  • FTSE

    7,000.08
    -19.45 (-0.28%)
     

  • Dow Jones

    34,077.63
    -123.04 (-0.36%)
     

  • DAX

    15,368.39
    -91.36 (-0.59%)
     

  • Hang Seng

    29,106.15
    +136.44 (+0.47%)
     

  • NIKKEI 225

    29,221.68
    -463.69 (-1.56%)
     
Sign up here 📩:

Get the latest business, economy and property news, delivered straight to you.

Stay informed every day with Yahoo Finance's free Fully Briefed newsletter.

'Most-used cooking appliance we own': Shoppers love this voice-controlled smart air fryer that’s big enough to feed a family

Moriba Cummings
·3-min read

Our team is dedicated to finding and telling you more about the products and deals we love. If you love them too and decide to purchase through the links below, we may receive a commission. Pricing and availability are subject to change.

Proscenic has garnered a reputation for building some of today’s best high-quality smart devices that make life so much easier. From its two-in-one robot vacuum to its powerful and advanced air purifier, the tech brand rarely ever misses.

The latest smart device to join Proscenic’s high-powered lineup is its new T21 Smart Air Fryer that has eight cooking presents, an LED touchscreen, Amazon Alexa integration and more. Also, shoppers even say it’s currently their “most-used cooking appliance.”

Proscenic T21 Smart Air Fryer With App And Alexa Voice Control, $129

Credit: Amazon
Credit: Amazon

Buy Now on Amazon

Buy Now on Proscenic

While air fryers, in general, are having a moment right now, offering healthier cooking alternatives to deep frying, this particular option differs from the rest, thanks to a few special features.

What sets the Proscenic T21 Smart Air Fryer apart from others?

Firstly, the Proscenic T21 Smart Air Fryer has Wi-Fi connectivity built-in. This allows it to integrate with Amazon Alexa or Google Assistant seamlessly. Simply put, this feature lets you control the appliance with your voice.

By just speaking a command, you can turn the device off and on, schedule the cooking, adjust and monitor the cooking process, customize your own recipes and more. This is all possible with the Proscenic Home app.

It’s perfect for both pros and beginners

If you’re new to the air frying practice, this is also the perfect option for you as there are tons of recipes available on the app for you to follow. As an added bonus, you can even tweak and customize your own recipes and save them to the app for further reference.

Credit: Proscenic
Credit: Proscenic

The countertop device also comes with three combination functions: “schedule”, “menu” and “keep warm”. This unique function is exclusive to the Proscenic air fryer and can be used in a combination of ways or individually.

If you own a dishwasher and particularly despise washing the detachable basket after use, you’d be happy to learn that the T21 Smart Air Fryer’s basket is both non-stick and dishwasher safe. In fact, each detachable part of the appliance is dishwasher safe.

What do shoppers think of this air fryer?

Shoppers also particularly love how easy this air fryer is to use, with several reviewers praising its seamless functionality thanks to its LED one-touch screen and app.

With an average customer rating of 4.6 out of 5 stars and over 3,700 five-star reviews, this air fryer is quickly becoming a customer favorite, despite its recent release.

One element shoppers love most is that the detachable basket is larger than most air fryers, making it easier to feed a large family with one single use.

“Every air fryer I have seen has been small and doesn’t have enough room to cook enough for a few people to eat,” one shopper wrote. “I love [this one]. Not only does it have enough room to cook for my girlfriend, our kid and I, but it is super easy to use.”

Another shopper who dubbed it their “most used cooking appliance” said it’s easy, quick and extremely “addicting” — in the best way possible.

“We’re always saying, ‘What else can we try?'” the shopper said. “So far, we’ve done hot wings, salmon, hot Cheetos crush chicken breast, orange chicken and more!”

If you enjoyed this story, check out the 8 best office chairs for working from home, according to reviewers.

More from In The Know:

How to teach Black History beyond February

This No. 1 best-selling air purifier ‘removes dust from the air’ before your very eyes — and it’s on sale

This 6-in-1 cubic power strip has over 23,000 five-star reviews on Amazon

I understand why over 18,000 Amazon reviewers love this touch desk lamp

The post Hundreds of shoppers say this Wi-Fi-enabled, voice-controlled smart air fryer is their ‘most-used appliance’ appeared first on In The Know.

Latest stories

  • ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Leidos Holdings, Inc. Investors with Losses to Secure Counsel Before Important May 3 Deadline in Securities Class Action – LDOS

    NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Leidos Holdings, Inc. (NYSE: LDOS) between May 4, 2020 and February 23, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff deadline. SO WHAT: If you purchased Leidos securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Leidos class action, go to http://www.rosenlegal.com/cases-register-2035.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the purported benefits of Leidos’ acquisition of L3Harris’ Security Detection & Automation businesses were significantly overstated; (2) Leidos’ products suffered from numerous product defects, including faulty explosive detection systems at airports, ports, and borders; (3) as a result of the foregoing, Leidos’ financial results were significantly overstated; and (4) as a result of the foregoing, defendants’ positive statements about Leidos’ business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Leidos class action, go to http://www.rosenlegal.com/cases-register-2035.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com cases@rosenlegal.com www.rosenlegal.com

  • Asia Stocks Track U.S. Lower; Bonds, Yen Rally: Markets Wrap

    (Bloomberg) -- Asia stocks slipped at the open Tuesday after weakness in the technology sector pulled U.S. indexes from all-time peaks, with investors weighing corporate earnings and recent spikes in virus cases. The yen hit its strongest level since early March.Shares fell in Japan and Australia and futures pointed lower in Hong Kong. U.S. contracts edged higher. The tech-heavy Nasdaq 100 Index underperformed in the U.S. session, while the S&P 500 Index also fell. Tesla Inc. led the declines after concerns about a fatal crash of one of its electric vehicles, which appeared to have no driver.Treasury yields slipped back below 1.6% and the dollar dipped.Investors are awaiting further confirmation of the private sector’s recovery from the pandemic as the earnings season gathers pace. The bright spot in the latest reports was the first revenue gain for International Business Machines Corp. in eleven quarters. Even with this latest pullback in major indexes, and the latest grim news on the spread of Covid-19, global stocks are trading near record highs.“We do think the market is a little overextended here,” Dave Sekera, chief U.S. market strategist at Morningstar Investment Services, told Bloomberg TV, adding that broad U.S. equities look about 5% overvalued. “Having said that we do still see value in a couple of areas, the value category being one.”Here are some key events to watch this week:Apple’s first product unveiling of the year on Tuesday.Reserve Bank of Australia releases minutes of its policy meeting on Tuesday.EIA crude oil inventory report on Wednesday.European Central Bank rate decision and President Christine Lagarde briefing on Thursday.U.S. releases new home sales dataThese are some of the main moves in markets:StocksS&P 500 futures were up 0.2% as of 9:05 a.m. in Tokyo. The S&P 500 fell 0.5%. The Nasdaq 100 fell 1%Japan’s Topix Index slid 1.5%Korea’s Kospi Index edged up 0.2%Australia’s S&P/ASX 200 Index slipped 0.4%Hong Kong’s Hang Seng Index futures retreated 0.5%CurrenciesThe yen extended overnight gains, rising 0.2% to 108.02 per dollarThe offshore yuan was at 6.5083 per dollarThe Bloomberg Dollar Spot Index fell 0.1%The euro was at $1.2044BondsThe yield on 10-year Treasuries slipped one basis point to 1.59%CommoditiesWest Texas Intermediate crude rose 0.2% to $63.50 a barrelGold was up 0.1% at $1,772.58 an ounceFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Keir Starmer urges government to block English clubs’ involvement in European Super League

    EXCLUSIVE: The Labour Party leader is also in favour of limiting ownership to reduce the amount of control clubs such as the current ‘Big Six’ occupy

  • UPDATE 1-Soccer-New league designed to save football, says Real president

    A controversial decision to form a breakaway European Super League was taken “to save football” and in part motivated because “young people are no longer interested” in the game, Real Madrid president Florentino Perez said on Tuesday. Speaking for the first time since 12 top European clubs announced on Sunday that they would form a new elite league, the new chairman of the Super League said football needed to evolve and adapt to the times. "Whenever there is a change, there are always people who oppose it... and we are doing this to save football at this critical moment," Perez said on the Spanish TV show El Chiringuito de Jugones.

  • Merkel party backs Laschet as chancellor candidate

    Angela Merkel's party early on Tuesday firmly backed Armin Laschet to be the conservative bloc's chancellor candidate at Germany's upcoming elections, hoping to draw a line under a bitter battle with challenger Markus Soeder.

  • David Beckham on controversial soccer Super League: 'the game we love is in danger'

    Beckham's comments were ironic, though, coming from the co-owner of a club in a closed league.

  • XL INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages XL Fleet Corp. Investors to Secure Counsel Before Important May 7 Deadline in Securities Class Action – XL

    NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of XL Fleet Corp. (NYSE: XL) between October 2, 2020 and March 2, 2021, inclusive (the “Class Period”), of the important May 7, 2021 lead plaintiff deadline. SO WHAT: If you purchased XL Fleet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the XL Fleet class action, go to http://www.rosenlegal.com/cases-register-2055.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 7, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) XL Fleet’s salespeople were pressured to inflate their sales pipelines to boost the Company’s reported sales and backlog; (2) at least 18 of the 33 customers that XL Fleet featured were inactive and had not placed an order since 2019; (3) XL Fleet’s technology had been materially overstated and offered only 5% to 10% of fleet savings; (4) XL Fleet lacks the supply chain and engineers to roll out new products on the announced timeline; and (5) as a result of the foregoing, defendants’ positive statements about XL Fleet’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the XL Fleet class action, go to http://www.rosenlegal.com/cases-register-2055.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com cases@rosenlegal.com www.rosenlegal.com

  • 'Not obsessed': Novak Djokovic fires back at spicy Rafa Nadal claim

    Novak Djokovic hit back at Rafa Nadal's spicy claims about the World No.1's 'obsession' with records.

  • Why GameStop Stock Popped Today

    What happened Shares of GameStop (NYSE: GME) rose 6.3% Monday after the video game retailer announced its CEO succession plan.  So what Current CEO George Sherman will step down on July 31, or potentially sooner if a new chief executive is found.

  • Billionaire Fungs Weigh Sale of Luxury Bagmaker Delvaux

    (Bloomberg) -- Hong Kong billionaire brothers Victor and William Fung are exploring selling their stake in Delvaux, a 192-year-old Belgian luxury leather bagmaker, people with knowledge of the matter said.The Fungs are working with advisers and have reached out to prospective suitors on the potential divestment of the asset, the people said. A sale could value the bagmaker at around $500 million to $600 million, said the people, who asked not to be identified as the information is private.The brothers acquired the stake together with Singaporean state investment company Temasek Holdings Pte in a 2011 deal, giving the two parties majority control of the company, they said.Deliberations are ongoing and the Fungs could decide to keep their stake in the business, according to the people. A representative for Fung Group had no immediate comment. A spokesperson for Temasek declined to comment.Founded in 1829 by Charles Delvaux in Brussels, the brand was granted the title “Purveyor to the Court” in 1883, supplying leather goods to the Royal Court of Belgium, according to its website.The Fung brothers and Temasek have been expanding the brand’s store networks, especially in China, and its online offerings. The company announced a restructuring in February to shift quality control and distribution operations from Belgium to France, which could result in 26 job cuts, according to a report in Women’s Wear Daily citing a statement by the firm.Prices for Delvaux’s Brilliant bag, which features a top handle and a buckle lock, start at $4,700, according to its U.S. web store.(Updates with restructuring report in sixth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • UPDATE 1-Thousands of Rogers wireless service users report outage

    Rogers Communications Inc's customers using wireless voice and data services faced intermittent interruptions for several hours, the Canadian cellular and cable operator said in response to complaints on social media on Monday. Residential and business wireline internet services were not impacted, the company said in a tweet https://twitter.com/RogersHelps/status/1384200104555401216, adding that it was working on restoring the wireless services that were affected. Rogers said in a tweet https://twitter.com/RogersHelps/status/1384292493601087488 later in the day that wireless calls, SMS and data services were starting to return to normal for its customers and it would take several more hours for all customers and regions to return to full service.

  • Bursor & Fisher P.A. Announces Pendency of Federal Securities Claims Against Robinhood and Related Lead Plaintiff Deadline

    Bursor & Fisher, P.A., a consumer rights litigation firm, announces that a lawsuit is pending in the Southern District of Florida alleging that Robinhood Financial, LLC, Robinhood Securities, LLC, and Robinhood Markets, Inc. ("Robinhood") prohibited "their customers from buying multiple publicly traded stocks, including but not limited to GameStop ("GME"), AMC Entertainment ("AMC"), American Airlines ("AAL"), Nokia ("NOK"), BlackBerry Limited ("BB"), Bed Bath & Beyond ("BBBY"), Express ("EXPR"), Koss Corporation ("KOSS"), Naked Brand Group ("NAKD"), Sundial Growers, Inc., ("SNDL"), Tootsie Roll Industries ("TR"), and Trivago NV ("TRVG") (collectively, the "Stocks"), during an unprecedented rise in valuation for the aforementioned Stocks" in January 2021, in violations of federal securities laws. The lawsuit alleges violation of Section 10(b) of the Securities Exchange Act of 1934, 15 U.S.C. § 78(j)(b), and Rule 10b-5 promulgated thereunder by the SEC. 17 C.F.R. § 240.10b-5. The lawsuit, captioned Quat, et al. v. Robinhood Financial, LLC, et al., is pending in the Southern District of Florida under docket number 1:21-cv-21404. It has been consolidated into the multidistrict litigation In re: January 2021 Short Squeeze Trading Litigation, Case No. 1:21-md-02989-CMA (S.D. Fl.).

  • RIDE BREAKING NEWS: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Lordstown Motors Corp. f/k/a DiamondPeak Holdings Corp. Investors with Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action – RIDE, DPHC

    NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds: (i) purchasers of the securities of Lordstown Motors Corp. f/k/a DiamondPeak Holdings Corp. (NASDAQ: RIDE, DPHC) between August 3, 2020 and March 24, 2021, inclusive; and (ii) all holders of DiamondPeak common stock entitled to participate in the August 22, 2020 shareholder vote on the merger with Lordstown (the “Class Period”), of the important May 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased Lordstown securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Lordstown class action, go to http://www.rosenlegal.com/cases-register-2056.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Lordstown’s purported pre-orders were non-binding; (2) many of the would-be customers who made these purported pre-orders lacked the means to make such purchases and/or would not have credible demand for Lordstown’s Endurance; (3) Lordstown is not and has not been “on track” to commence production of the Endurance in September 2021; (4) the first test run of the Endurance led to the vehicle bursting into flames within 10 minutes; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Lordstown class action, go to http://www.rosenlegal.com/cases-register-2056.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq.Phillip Kim, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827lrosen@rosenlegal.compkim@rosenlegal.comcases@rosenlegal.comwww.rosenlegal.com

  • Chauvin Jury Gets Case After Emotional Day of Closing Arguments

    (Bloomberg) -- The case of the former Minneapolis police officer accused of killing George Floyd went to the jury after Derek Chauvin’s defense attorney said the viral video of him kneeling on Floyd’s neck and back doesn’t tell the entire story.Moments after jurors went into deliberation, defense attorney Eric Nelson pleaded with Judge Peter Cahill to declare a mistrial, pointing to the “public context” and “profound” media attention of the trial, including criticisms from Rep. Maxine Waters (D-Calif.) and television shows. Waters urged protesters to “get more confrontational” if Chauvin isn’t convicted, according to news reports.Cahill shot down Nelson’s bid, though he acknowledged that the defense may have something to work with on appeal.“A congresswoman’s opinion really doesn’t matter a whole lot,” Cahill said.The closing arguments come amid heightened tension in Minnesota and nationwide over police use of force. A 20-year-old Black man, Daunte Wright, was shot and killed by an officer in nearby Brooklyn Center, Minn., during the Floyd trial, spurring protests that could possibly erupt further following a verdict in the Chauvin trial. Nelson has spent the trial laying groundwork for potential appeals if Chauvin is convicted, arguing Cahill should have sequestered the jury sooner to keep them from being influenced by news coverage.The jury will decide if the state proved Chauvin is guilty of second-degree murder, third-degree murder or manslaughter. Chauvin faces up to 40 years in prison.Nelson in his closing argument broke down videos of Floyd’s arrest on May 25, 2020, to show the various decisions Chauvin and other officers had to make in the moment as they sought to subdue the suspect safely.Chauvin had to evaluate how aggressive Floyd was and whether he posed a risk to police officers or bystanders shouting at officers as they sought to arrest him. Officers were constantly evaluating Floyd’s resistance and health, Nelson said as he walked jurors through video of Floyd’s arrest and death.“A reasonable officer should be able to use a reasonable amount of force to overcome a suspect’s resistance,” Nelson told jurors.Arrest FootagePolice were called to Cup Foods in Minneapolis May 25, 2020, after reports that a customer used a possible counterfeit bill. According to body camera footage shown to jurors, Floyd became agitated when officers approached him in his car with their guns drawn. He shouted he was afraid of being shot, echoing what he said during a 2019 traffic stop also shown to jurors.The confrontation escalated after police got Floyd out of his car and attempted to put him in the back of a squad car. Floyd screamed he was claustrophobic and couldn’t breathe.Chauvin arrived on the scene to assist two rookies — one of whom Chauvin trained — attempting to arrest Floyd. Chauvin had to make a series of snap decisions to assess the risks Floyd posed to police and bystanders, Nelson said.When officers were struggling to get Floyd into a police car, “not a single use of force expert who testified, not a single police officer who testified said anything that happened to this point was unreasonable,” Nelson said.The “dispute” over whether Chauvin killed Floyd begins when officers pulled Floyd to the ground after he refused to get into the car. Nelson broke down video of officers restraining Floyd to show they were assessing the suspect’s health and whether further force was warranted, showing Chauvin was following police procedure, Nelson said.‘Betrayed the Badge’The prosecution in its closing arguments emphasized that only Chauvin is on trial and not the practice of policing itself.Special prosecutor Steve Schleicher praised the “most noble profession of policing” while making his final argument that Chauvin should be found guilty in Floyd’s death. Schleicher laid out the case that Chauvin violated police department policy and training when he was filmed kneeling on Floyd’s neck for more than nine minutes on May 25, 2020, painting Chauvin as a rogue actor.“What the defendant did was not policing. What the defendant did was an assault,” Schleicher said during closing arguments. “There’s nothing worse for good police than bad police.”Chauvin “betrayed the badge and everything it stood for,” he added.Prosecutors posited that police ignored Floyd’s cries for help amid the arrest and during his struggle. Schleicher said that Floyd near the end of his life referred to Chauvin as “Mr. Officer.”“We call the police when we need help. And he pleaded with Mr. Officer,” Schleicher said. “He asked for help with his very last breath. But Mr. Officer did not help, the defendant did not help, he stayed on top of him.”Schleicher showed footage of Floyd’s arrest to the jurors to make the case that Chauvin and the other officers failed to provide aid as required by department training and policy. Rather than rolling Floyd to his side to aid his breathing, as is required, the officers held Floyd prone while he shouted he couldn’t breathe.Garland’s ViewU.S. Attorney General Merrick Garland urged the public to wait for the verdict in the Chauvin trial while adding that racism still plagues the country.“We do not yet have equal justice under law,” Garland said in an interview that aired Monday with ABC News. The Justice Department has an ongoing investigation into whether Chauvin violated federal civil rights laws, which will continue regardless of the verdict in the murder trial.Asked if he believes there’s racism and bias within law enforcement agencies, Garland said, “Racism is an American problem. It’s plain to me that there has been and remains discrimination against African Americans and other communities of color, and other ethnic minorities.”Finishing the state’s argument to the jury Monday, special prosecutor Jerry Blackwell pushed back on defense claims that Floyd died from an enlarged heart.“The reason George Floyd is dead is because Mr. Chauvin’s heart is too small,” Blackwell said.To contact the reporters on this story: Ayanna Alexander in Washington at aalexander@bloomberglaw.com; Ian Lopez in Washington at ilopez@bloomberglaw.comTo contact the editor responsible for this story: Andrew Childers at achilders@bloomberglaw.com(Updates with Attorney General Garland’s comments under ‘Garland’s View’ subheadline)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Derek Chauvin defence team seeks mistrial over Congresswoman Maxine Waters’ comments — but judge rules it out

    If a mistrial is declared, a defendant is neither convicted nor acquitted

  • Australia's COVID-19 win to help fuel economic growth this year: Reuters poll

    The Australian economy will grow this year at its fastest pace since 2007, driven by massive stimulus and as the country has largely been able to contain the transmission of the novel coronavirus unlike its rich-world peers, a Reuters poll showed. At a time when most major economies are battling a fresh wave of coronavirus cases, Australia has largely curtailed the outbreak, counting only about 30,000 local infections and 910 deaths since the start of the pandemic. After contracting at a much slower pace than its peers at around 2.5% last year, Australia's A$2 trillion economy was forecast to expand on average by 4.4% this year, according to an April 6-19 poll of 34 economists.

  • ‘I’m not going to be bullied’: Maxine Waters hits back at GOP criticism after she urged protesters to get ‘more confrontational’ in Minneapolis

    Congresswoman’s comments come as jury set to consider verdict in Derek Chauvin murder trial

  • Nomura Asset Management Co., Ltd. Expands Use of Cloud-Based Charles River IMS

    Charles River Development announces Nomura Asset Management Co., Ltd. is expanding their use of the Charles River Investment Management Solution.

  • ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BELLUS Health Inc. Investors with Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action – BLU

    NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”), of the important May 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased BELLUS securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the BELLUS class action, go to http://www.rosenlegal.com/cases-register-2058.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose information that resulted in a scheme that: (1) deceived the investing public regarding BELLUS’s business, operations, drug products, drug product development, competition, and present and future business prospects; (2) facilitated the Company’s September 2019 public offering (“Offering”); (3) created artificial demand for the BELLUS common shares sold in the Offering; (4) enabled the Company to receive approximately $70 million in net proceeds from the sale of BELLUS common stock in the Offering; and (5) caused purchases of BELLUS publicly traded common stock at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the BELLUS class action, go to http://www.rosenlegal.com/cases-register-2058.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com cases@rosenlegal.com www.rosenlegal.com

  • Rett Syndrome Clinical Trials Review: An Updated Status Report on Emerging Drugs by DelveInsight

    The report offers the most up-to-date information on Rett Syndrome pipeline products being developed by notable companies such as Anavex Life Sciences Corp., GW Research Ltd, Neuren Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Edison Pharmaceuticals, Novartis, Neurolixis, Echo Pharmaceuticals, Relmada Therapeutics, and others.Los Angeles, USA , April 19, 2021 (GLOBE NEWSWIRE) -- Rett Syndrome Clinical Trials Review: An Updated Status Report on Emerging Drugs by DelveInsight The report offers the most up-to-date information on Rett Syndrome pipeline products being developed by notable companies such as Anavex Life Sciences Corp., GW Research Ltd, Neuren Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Edison Pharmaceuticals, Novartis, Neurolixis, Echo Pharmaceuticals, Relmada Therapeutics, and others. DelveInsight’s “Rett Syndrome Pipeline Insight” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Rett Syndrome pipeline landscapes. It comprises Rett Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Rett Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Rett Syndrome pipeline products. Some of the key takeaways of the Rett Syndrome Pipeline Report There is no cure for Rett syndrome. Around 8+ key companies are developing Rett Syndrome therapies. These key players are Anavex Life Sciences Corp., GW Research Ltd, Neuren Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Edison Pharmaceuticals, Novartis, Neurolixis, Echo Pharmaceuticals, Relmada Therapeutics, and others have their Rett Syndrome drug candidates in the different phases of clinical development. Trofinetide is a novel synthetic analogue of the amino‐terminal tripeptide of IGF-1 designed to treat the Rett Syndrome symptoms. Acadia has an exclusive license for developing and commercialising trofinetide in North America from Neuren Pharmaceuticals. The drug is in Phase III clinical evaluation for the treatment of Rett Syndrome.The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted Orphan Drug designation to Neuren for trofinetide in Rett Syndrome. The FDA has also accorded Fast Track designation.In February 2020, GW Research initiated a phase III trial to investigate the long-term safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome. The trial is anticipated to be finished by June 2022.NLX-101 (previously known as F15599) is a Phase I drug intended to treat Rett's syndrome. It is a novel compound that activates serotonin 5-HT1A receptors with exceptional selectivity, having over 1000-fold higher affinity for this target over other receptors. Also, NLX-101 is a 'biased agonist' at 5-HT1A receptors, preferentially activating 5-HT1A receptors in those brain regions that control mood and cognition. The FDA and the EMA have awarded NLX-101 Orphan Drug Status. Get an overview of pipeline landscape @ Rett Syndrome Clinical Trials Analysis Rett Syndrome is a neurodevelopmental disorder, which affects girls almost exclusively. It is characterised by average early growth and development followed by a decrease of development, loss of purposeful use of the hands, distinctive hand movements, decreased brain and head growth, walking, seizures, and intellectual disability. There is no cure for the disease. Rett Syndrome treatment is symptomatic, focusing on managing symptoms and supportive, needing a multidisciplinary approach. Medication may be required for breathing irregularities and motor difficulties, and anticonvulsant drugs may be utilised to control seizures. Occupational therapy can benefit children develop skills required for performing self-directed activities, while physical therapy and hydrotherapy may prolong mobility. Rett Syndrome Emerging Drugs Trofinetide by Neuren Pharmaceuticals Trofinetide is a novel synthetic analogue of the amino‐terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett Syndrome by reducing neuroinflammation and supporting synaptic function. Research and Development Phase III NCT04181723: ACADIA Pharmaceuticals, in November 2019, initiated a Phase III study titled “Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women with Rett Syndrome”. With an estimated 184 participants, the trial is currently in recruiting stage and expected to be completed by October 2021. Neuren's North American partner for trofinetide, ACADIA Pharmaceuticals, has commenced a Phase 3 trial ("Lavender") in Rett syndrome. Neuren previously conducted a Phase 2 double-blind placebo-controlled clinical trial in girls aged 5 to 15 years with Rett syndrome. This followed positive trends observed in Neuren's earlier Phase 2 trial in adolescents and adults aged 16 to 45 years. For further information, refer to the detailed report @ Rett Syndrome Pipeline Therapeutics Scope of Rett Syndrome Pipeline Drug Insight Coverage: Global Major Players: 8+ Key PlayersProminent Players: Anavex Life Sciences Corp., GW Research Ltd, Neuren Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Edison Pharmaceuticals, Novartis, Neurolixis, Echo Pharmaceuticals, Relmada Therapeutics, and many others. Key Drugs Profiles: 8+ Products Phases: Rett Syndrome Therapies Late-stage (Phase III) Rett Syndrome Therapies Mid-stage (Phase II)Rett Syndrome Therapies Early-stage (Phase I) Rett Syndrome Pre-clinical stage and Discovery candidates Discontinued and Inactive candidates Mechanism of Action: Sigma-1 receptor agonistsCannabinoid receptor CB1, CB2 inverse agonistsCytokine inhibitors Molecule Types: Stem cell therapy Small molecule Gene therapy Route of Administration: InhalationIntravenous Oral Subcutaneous Product Types: MonotherapyCombinationMono/Combination Key Questions regarding Current Rett Syndrome Treatment Landscape and Emerging Therapies Answered in the Pipeline Report What are the current options for Rett Syndrome treatment?How many companies are developing therapies for the treatment of Rett Syndrome? How many are Rett Syndrome emerging therapies in the early-stage, mid-stage, and late development stages to treat Rett Syndrome?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Rett Syndrome market? Which are the dormant and discontinued products and the reasons for the same?What is the unmet need for current therapies for the treatment of Rett Syndrome? What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Rett Syndrome therapies? What are the critical designations that have been granted for the emerging therapies for Rett Syndrome? How many patents are granted and pending for the emerging therapies to treat Rett Syndrome? Table of Contents 1Rett Syndrome Introduction2Rett Syndrome Executive Summary3Rett Syndrome Overview4Rett Syndrome- Analytical Perspective In-depth Commercial Assessment5Rett Syndrome Pipeline Therapeutics6Rett Syndrome Late Stage Products (Registered)7Rett Syndrome Late Stage Products (Phase III)7.1Trofinetide: Neuren Pharmaceuticals7.2GWP42003-P: GW Research Ltd.8Rett Syndrome Mid Stage Products (Phase II/III)8.1ANAVEX2-73 oral liquid: Anavex Life Sciences Corp.9Rett Syndrome Mid Stage Products (Phase II)9.1Triheptanoin: Ultragenyx Pharmaceutical Inc.10Rett Syndrome Early Stage Products (Phase I)10.1NLX 101: Neurolixis11Rett Syndrome Pre-clinical and Discovery Stage Products12Rett Syndrome Therapeutic Assessment13Rett Syndrome Inactive Products14Company-University Collaborations (Licensing/Partnering) Analysis15Rett Syndrome Key Companies16Rett Syndrome Key Products17Rett Syndrome Unmet Needs18 Rett Syndrome Market Drivers and Barriers19Rett Syndrome Future Perspectives and Conclusion20Rett Syndrome Analyst Views21Appendix22About DelveInsight Get a customised pipeline report @ Rett Syndrome Drugs Pipeline Report Related Reports Rett Syndrome Market DelveInsight's Rett Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Rett Syndrome Epidemiology Forecast DelveInsight's Rett Syndrome - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Rett Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Acute Coronary Syndrome Market DelveInsight's Acute Coronary Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Aicardi Goutieres Syndrome Market DelveInsight's Aicardi Goutieres Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Alagille Syndrome Market DelveInsight's Alagille Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com